Wird geladen...
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
INTRODUCTION: Body weight can affect exposure, safety and efficacy of antibody-based therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved for wild-type RAS metastatic colorectal cancer, using a body weight–based dosing regimen. Recently, a report cited fixed-dos...
Gespeichert in:
| Veröffentlicht in: | Clin Pharmacol |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7406372/ https://ncbi.nlm.nih.gov/pubmed/32801947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S262949 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|